Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22993
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGregory, Gareth P-
dc.contributor.authorCarrington, Christine-
dc.contributor.authorCheah, Chan Y-
dc.contributor.authorHawkes, Eliza A-
dc.contributor.authorIrving, Ian M-
dc.contributor.authorSiderov, Jim-
dc.contributor.authorOpat, Stephen-
dc.date2020-04-14-
dc.date.accessioned2020-04-17T00:40:14Z-
dc.date.available2020-04-17T00:40:14Z-
dc.date.issued2020-08-
dc.identifier.citationAsia-Pacific journal of clinical oncology 2020; 16(4): 211-221en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22993-
dc.description.abstractDespite their availability for over a decade, the exact nature of biosimilar medicines is still poorly understood with paucity of clear treatment guidelines for their use in clinical practice in Australia. Although hematologists have had experience with biosimilars in the setting of supportive care, with the approval of the first biosimilar rituximab in hematological malignancies, it is important to revisit this topic. To inform the use of biosimilar medicines in clinical practice, we have developed a consensus statement from an Expert Panel of Australian hematologists, oncologists, and cancer pharmacists. These recommendations address the approach to use of biosimilar products in place of the corresponding reference medicine in a number of different clinical contexts. Our recommendations are based on the premise that biosimilar medicines can be considered therapeutically equivalent to their reference brand and used in a similar way to the reference product in any approved indication. We advocate for local approaches to the provision of patient information, dispensing of the intended brand and pharmacovigilance, to be developed in consultation with local hematologists and aim to improve confidence in the appropriate use of biosimilar medicines and their expected outcomes among hematologists.en
dc.language.isoeng-
dc.subjectbiosimilarsen
dc.subjectconsensus statementen
dc.subjecthematologyen
dc.titleA consensus statement on the use of biosimilar medicines in hematology in Australia.en
dc.typeJournal Articleen
dc.identifier.journaltitleAsia-Pacific journal of clinical oncologyen
dc.identifier.affiliationMonash Haematology, Monash Health, Clayton, Victoria, Australiaen
dc.identifier.affiliationDepartment of Pharmacy, Princess Alexandra Hospital, Brisbane, Queensland, Australiaen
dc.identifier.affiliationMedical School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia, Australiaen
dc.identifier.affiliationSir Charles Gairdner Hospital and Pathwest Laboratory Medicine WA, Nedlands, Western Australia, Australiaen
dc.identifier.affiliationPharmacy Department, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationClinical Haematology, Alfred Health, Melbourne, Victoria, Australiaen
dc.identifier.affiliationSchool of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australiaen
dc.identifier.affiliationSchool of Pharmacy, University of Queensland, Brisbane, Queensland, Australiaen
dc.identifier.affiliationEastern Health, Melbourne, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationIcon Group, Brisbane, Queensland, Australiaen
dc.identifier.affiliationThe Wesley Hospital, Auchenflower, Queensland, Australiaen
dc.identifier.doi10.1111/ajco.13337en
dc.type.contentTexten
dc.identifier.orcid0000-0002-4170-0682en
dc.identifier.orcid0000-0002-7372-1154en
dc.identifier.pubmedid32285612-
dc.type.austinJournal Article-
dc.type.austinReview-
local.name.researcherHawkes, Eliza A
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.